News

Pathway in the News:

June 20, 2011
Pathway: Function follows PI3K isoform
Emerging Company Profile: BioCentury, The Bernstein Report on BioBusiness

May 26, 2011
‘G’day’ for Pathway: $7.5M for PWT33597 Cancer Phase 1
BioWorld Today

Press Releases:

August 15, 2011
Pathway Therapeutics Announces Appointment of Mark Perry and Dr. Paul Goddard to its Board of Directors

May 25, 2011
FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio

August 10, 2010
Pathway Therapeutics Completes $4.5 Million Financing for Novel PI3K Inhibitor Portfolio

October 9, 2009
Pathway Therapeutics Completes $3 Million Financing for Cancer Programs and appoints Dr. Julie Cherrington as Chief Executive Officer

December 4, 2008
Pathway Therapeutics, a New Zealand drug development company, is the first recipient of funding from the Trans Tasman Commercialisation Fund (TTCF)

June 18, 2008
$10million for Pathway cancer drugs

Presentations

2011 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics presentation
PWT33597 promotes apoptosis in tumor cells through balanced, dual inhibition of PI3K alpha and mTOR